Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data of Glioma Stem Cells sorted for CD133 and PDPN expression

ABSTRACT: Expression data of Glioma Stem Cells sorted for CD133 and PDPN expression

PROVIDER: PRJNA835079 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data of Glioma Stem Cells sorted for CD133 and PDPN expression

Project description:Expression data of Glioma Stem Cells sorted for CD133 and PDPN expression.

2022-05-05 | GSE202221 | GEO

Three human glioma stem cell lines sorted for CD133 and one human neural precursor line sorted for CD133 to identify tumor-specific miRNA dysregulation.

Project description:Several novel potential oncogenic and tumor suppressor miRNAs were identified by using the appropriate controls for stem cells. Expression profiles for human miRNAs in six samples were generated. The Agilent platform GPL7731 was used to analyze six RNA samples: CD133- human NPC, CD133+ human NPC, CD133- B4 glioma, CD133+ B4 Glioma, CD133+ NCH441 glioma, CD133+ NCH644 glioma

2013-08-02 | E-GEOD-49470 | biostudies-arrayexpress

Expression data from CD133+ and CD133- glioma cells

Project description:Given the very substantial heterogeneity of most human cancers, it is likely that most cancer therapeutics will be active in only a small fraction of any population of patients. As such, the development of new therapeutics, coupled with methods to match a therapy with the individual patient, will be critical to achieving significant gains in disease outcome. One such opportunity is the use of expression signatures to identify key oncogenic phenotypes that can serve not only as biomarkers but also as a means of identifying therapeutic compounds that might specifically target these phenotypes. Given the potential importance of targeting tumors exhibiting a stem-like phenotype, we have developed an expression signature that reflects common biological aspects of various stem-like characteristics. The Consensus Stemness Ranking (CSR) signature is upregulated in cancer stem cell enriched samples, at advanced tumor stages and is associated with poor prognosis in multiple cancer types. Using two independent computational approaches we utilized the CSR signature to identify clinically useful compounds that could target the CSR phenotype. In vitro assays confirmed selectivity of several predicted compounds including topoisomerase inhibitors and resveratrol towards breast cancer cell lines that exhibit a high-CSR phenotype. Importantly, the CSR signature could predict clinical response of breast cancer patients to a neoadjuvant regimen that included a CSR-specific agent. Collectively, these results suggest therapeutic opportunities to target the CSR phenotype in a relevant cohort of cancer patients. CD133+ and CD133- cells were separated from two glioma xenograft tumors. Both CD133+ and CD133- glioma cells were cultured in serum-free media for 48 hours in the presence of absence of laminin.

2010-10-16 | E-GEOD-24716 | biostudies-arrayexpress

Expression of FACS-sorted CD133+ and CD133- cells of three gastric cell lines

Project description:To identify the gene expression signature associated with CD133, the well-known stem cell markers, three gastric cancer cell lines were obtained (KATO-III, SNU201 and SNU601). Cultured gastric cancer celllines were sorted into CD133+ and CD133- population by FACS sorting and microarray-based gene expression profiling was performed.

2018-04-04 | GSE112631 | GEO

Y79 Rb Cell line: CD133 positive vs CD133 negative cancer stem like cells

Project description:Gene expression and pathway analysis of sorted CD133 negative and CD133 positive population

2018-05-17 | GSE96657 | GEO

Expression of FACS-sorted CD133+ and CD133- cells of three gastric cell lines

Project description:Expression of FACS-sorted CD133+ and CD133- cells of three gastric cell lines

| PRJNA448577 | ENA

Expression data comparing Huh7 CD133+ and CD133- HCC cells

Project description:To identify candidate genes involved in enhanced tumorigenicity of CD133+ liver tumor-initiating cells Affymetrix Human Genome U133 Plus GeneChip 2.0 HCC cell line Huh7 was sorted into CD133+ and CD133- populations by flow cytometry

2012-04-04 | E-GEOD-23450 | biostudies-arrayexpress

Expression data comparing PLC8024 CD133+ and CD133- HCC cells

Project description:To identify candidate genes involved in enhanced tumorigenicity of CD133+ liver tumor-initiating cells Affymetrix Human Genome U133 Plus GeneChip 2.0 HCC cell line PLC8024 was sorted into CD133+ and CD133- populations by flow cytometry

2012-04-04 | E-GEOD-23451 | biostudies-arrayexpress

Expression data from 13 week human fetal scalp epidermis sorted for expression of alpha 6 integrin and CD133

Project description:CD133 is expressed by a subpopulation of human fetal hair follicle placode cells during early hair development. Its expression, which is gradually lost as the placode matures, correlates with early morphogenesis. We used microarrays to analyze differences in gene expression between alpha-6 integrin+CD133+ basal cells and other human fetal epidermal populations to provide candidates defining this unique hair follicle placode subpopulation. 13 week human fetal scalp epidermis was sorted into 3 populations based upon expression of alpha 6 integrin and CD133 and RNA analyzed for gene expression.

2014-07-01 | E-GEOD-58393 | biostudies-arrayexpress

Expression data comparing CD133+ and CD133- B16-F10 melanoma cells

Project description:Expression data comparing CD133+ and CD133- B16-F10 melanoma cells

| PRJNA534522 | ENA